<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543750</url>
  </required_header>
  <id_info>
    <org_study_id>CINCH-EA2</org_study_id>
    <secondary_id>R01FD003923</secondary_id>
    <nct_id>NCT01543750</nct_id>
  </id_info>
  <brief_title>4-Aminopyridine in Episodic Ataxia Type 2</brief_title>
  <acronym>4AP in EA2</acronym>
  <official_title>Phase 2 Study of 4-Aminopyridine for the Treatment of Episodic Ataxia Type 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Episodic ataxia type 2 (EA2) is a rare familial neurological condition characterized by
      debilitating episodes of vertigo and imbalance. Since the serendipitous discovery of dramatic
      response of EA2 to acetazolamide, acetazolamide has been the first-line treatment for EA2.
      Yet, for those patients who do not respond to or cannot tolerate acetazolamide, there is no
      alternative treatment. The purpose of this randomized trial is to test whether
      4-aminopyridine may reduce the ataxia episodes in EA2 as an alternative to acetazolamide.
      Funding Source - FDA OOPD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to determine whether 4-aminopyridine (4AP) can reduce attacks of ataxia in
      patients with episodic ataxia type 2 (EA2), a rare but often debilitating condition. Episodic
      ataxia (EA) is a group of inherited disorders characterized by recurrent, discrete episodes
      of vertigo and ataxia variably associated with progressive ataxia. EA2, the most common and
      the best characterized of all the EA syndromes, is caused by heterozygous mutations in
      CACNA1A, which encodes the main subunit of a neuronal voltage-gated calcium channel, Cav2.1.

      Although observational data suggest symptomatic resolution with acetazolamide in many EA2
      patients, the investigators found in our patient databases that at least a third of the EA2
      patients continue to suffer debilitating ataxia attacks, either because of incomplete control
      while on acetazolamide or because of intolerability or hypersensitivity to acetazolamide. For
      these patients there is no alternative intervention. 4-Aminopyridine (4AP) has been found to
      be helpful in a handful of patients with EA2. Recently, dalfampridine, an extended release
      formulation of 4AP (AMPYRA) by Acorda Therapeutics, received FDA approval to improve gait in
      multiple sclerosis.

      The investigators plan to recruit 20 subjects with genetically defined EA2 who suffer
      frequent ataxia episodes (at least 3 episodes a month) to conduct a randomized trial of 4AP
      to examine its efficacy and tolerability in EA2. Study subjects will be recruited at UCLA and
      the University of Rochester to participate in a randomized, double-blind, double-crossover
      trial of 4AP.Each treatment period is 2-months with a 1-week wash-out period in between each
      treatment period. Participating subjects will undergo standardized history and physical
      examination at the time of enrollment. Participants will log their ataxia attacks daily by
      interactive voice response (IVR) system and will be interviewed monthly for events and side
      effects/toxicity. Study visits will occur at the beginning and the end of the study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the frequency of ataxia episodes</measure>
    <time_frame>11 months</time_frame>
    <description>Trial participants have frequent episodes of ataxia at baseline. The participants will document daily whether ataxia events occurred during the 2-month screening period and the 9-month study period by calling a toll-free number and participating in an Interactive Voice Response (IVR) system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>impact on daily activities</measure>
    <time_frame>11 months</time_frame>
    <description>Participants will use IVR to log the impact (on a scale of 0-3) of ataxia events, if any, on their daily activities:
(0) No impact
(1) Mild
(2) Moderate
(3) Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of ataxia episodes</measure>
    <time_frame>11 months</time_frame>
    <description>Study Participants will use IVR daily to log the duration of ataxia events, if any, in hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severity of ataxia episodes</measure>
    <time_frame>11 months</time_frame>
    <description>Study Participants will use IVR daily to log the severity of ataxia events, if any, on a scale of 1-9:
(1) mild (9) very severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment satisfaction</measure>
    <time_frame>9 months</time_frame>
    <description>The study participant will respond by phone interview to the 11-item Treatment Satisfaction Questionnaire for Medication (TSQM Version 2) at the end of each of the four treatment periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>9 months</time_frame>
    <description>The study participant will be interviewed by phone regarding toxicity using the [Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0] at two different time points (4 weeks, 8 weeks) of each 8-week Treatment Period. Spectrum and severity of toxicity and the prevalence among study participants will be documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects</measure>
    <time_frame>9 months</time_frame>
    <description>The study participant will log side effects as they occur (reporting the seizures or other severe side effects immediately to Investigators) and will be interviewed by phone regarding side effects at two different time points (4 weeks, 8 weeks) of each 8-week Treatment Period. Spectrum of side effects and the prevalence among those treated will be documented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Episodic Ataxia Type 2</condition>
  <arm_group>
    <arm_group_label>Study Medication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4-aminopyridine 10mg twice daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo twice daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4-Aminopyridine</intervention_name>
    <arm_group_label>Study Medication</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients will be included if they:

          -  Have EA2 genetically confirmed to harbor mutations in CACNA1A

          -  Are ≥ 18 years of age

          -  Are not taking acetazolamide (because of intolerance, poor response, or allergy)

          -  Are able to maintain a daily log of ataxia episode(s) and report daily by using an
             Interactive Voice Recording System (IVR) throughout the study

          -  Experience ≥ 3 ataxia episodes per month during the two-month screening period to
             qualify for randomization

        Exclusion Criteria:

        Patients will be excluded if they:

          -  Have seizures or a history of seizures

          -  Have first-degree relatives with EA2 and seizures

          -  Have renal disease with impaired function (Creatinine clearance CrCl≤50ml/min)

          -  Are pregnant or breast feeding (women of childbearing age will be tested for pregnancy
             and must be using birth control)

          -  Are unable to comply with the study requirement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna C Jen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester School of Medicine</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/cinch/index.htm</url>
    <description>Consortium for the Clinical Investigation of Neurological Channelopathies (CINCH)</description>
  </link>
  <reference>
    <citation>Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004 Feb 26;2:12.</citation>
    <PMID>14987333</PMID>
  </reference>
  <reference>
    <citation>Bever CT Jr, Young D, Anderson PA, Krumholz A, Conway K, Leslie J, Eddington N, Plaisance KI, Panitch HS, Dhib-Jalbut S, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology. 1994 Jun;44(6):1054-9.</citation>
    <PMID>8208399</PMID>
  </reference>
  <reference>
    <citation>DuMouchel W, Groër PG. A Bayesian methodology for scaling radiation studies from animals to man. Health Phys. 1989;57 Suppl 1:411-8.</citation>
    <PMID>2606701</PMID>
  </reference>
  <reference>
    <citation>Glasauer S, Strupp M, Kalla R, Büttner U, Brandt T. Effect of 4-aminopyridine on upbeat and downbeat nystagmus elucidates the mechanism of downbeat nystagmus. Ann N Y Acad Sci. 2005 Apr;1039:528-31.</citation>
    <PMID>15827015</PMID>
  </reference>
  <reference>
    <citation>Griggs RC, Moxley RT 3rd, Lafrance RA, McQuillen J. Hereditary paroxysmal ataxia: response to acetazolamide. Neurology. 1978 Dec;28(12):1259-64.</citation>
    <PMID>366453</PMID>
  </reference>
  <reference>
    <citation>Imbrici P, Jaffe SL, Eunson LH, Davies NP, Herd C, Robertson R, Kullmann DM, Hanna MG. Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia. Brain. 2004 Dec;127(Pt 12):2682-92. Epub 2004 Oct 13.</citation>
    <PMID>15483044</PMID>
  </reference>
  <reference>
    <citation>Harno H, Heikkinen S, Kaunisto MA, Kallela M, Häkkinen AM, Wessman M, Färkkilä M, Lundbom N. Decreased cerebellar total creatine in episodic ataxia type 2: a 1H MRS study. Neurology. 2005 Feb 8;64(3):542-4.</citation>
    <PMID>15699392</PMID>
  </reference>
  <reference>
    <citation>Hoebeek FE, Stahl JS, van Alphen AM, Schonewille M, Luo C, Rutteman M, van den Maagdenberg AM, Molenaar PC, Goossens HH, Frens MA, De Zeeuw CI. Increased noise level of purkinje cell activities minimizes impact of their modulation during sensorimotor control. Neuron. 2005 Mar 24;45(6):953-65.</citation>
    <PMID>15797555</PMID>
  </reference>
  <reference>
    <citation>Jen J, Kim GW, Baloh RW. Clinical spectrum of episodic ataxia type 2. Neurology. 2004 Jan 13;62(1):17-22.</citation>
    <PMID>14718690</PMID>
  </reference>
  <reference>
    <citation>Jen JC, Graves TD, Hess EJ, Hanna MG, Griggs RC, Baloh RW; CINCH investigators. Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain. 2007 Oct;130(Pt 10):2484-93. Epub 2007 Jun 15. Review.</citation>
    <PMID>17575281</PMID>
  </reference>
  <reference>
    <citation>Jouvenceau A, Eunson LH, Spauschus A, Ramesh V, Zuberi SM, Kullmann DM, Hanna MG. Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel. Lancet. 2001 Sep 8;358(9284):801-7.</citation>
    <PMID>11564488</PMID>
  </reference>
  <reference>
    <citation>Löhle M, Schrempf W, Wolz M, Reichmann H, Storch A. Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2--a video case report. Mov Disord. 2008 Jul 15;23(9):1314-6. doi: 10.1002/mds.22071.</citation>
    <PMID>18442126</PMID>
  </reference>
  <reference>
    <citation>March B, Cardi T. Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals. Expert Opin Investig Drugs. 2009 Dec;18(12):1807-15. doi: 10.1517/13543780903443096.</citation>
    <PMID>19938897</PMID>
  </reference>
  <reference>
    <citation>McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med. 1989 Dec 7;321(23):1567-71.</citation>
    <PMID>2555713</PMID>
  </reference>
  <reference>
    <citation>Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, Lamerdin JE, Mohrenweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen GJ, Hofker MH, Ferrari MD, Frants RR. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996 Nov 1;87(3):543-52.</citation>
    <PMID>8898206</PMID>
  </reference>
  <reference>
    <citation>Palermo TM, Valenzuela D, Stork PP. A randomized trial of electronic versus paper pain diaries in children: impact on compliance, accuracy, and acceptability. Pain. 2004 Feb;107(3):213-9.</citation>
    <PMID>14736583</PMID>
  </reference>
  <reference>
    <citation>Sappey-Marinier D, Vighetto A, Peyron R, Broussolle E, Bonmartin A. Phosphorus and proton magnetic resonance spectroscopy in episodic ataxia type 2. Ann Neurol. 1999 Aug;46(2):256-9.</citation>
    <PMID>10443893</PMID>
  </reference>
  <reference>
    <citation>Smith W, Swan S, Marbury T, Henney H 3rd. Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment. J Clin Pharmacol. 2010 Feb;50(2):151-9. doi: 10.1177/0091270009344857. Epub 2009 Dec 4.</citation>
    <PMID>19966074</PMID>
  </reference>
  <reference>
    <citation>Spyker DA, Lynch C, Shabanowitz J, Sinn JA. Poisoning with 4-aminopyridine: report of three cases. Clin Toxicol. 1980 Jun;16(4):487-97.</citation>
    <PMID>6250762</PMID>
  </reference>
  <reference>
    <citation>Stefoski D, Davis FA, Faut M, Schauf CL. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol. 1987 Jan;21(1):71-7.</citation>
    <PMID>2435223</PMID>
  </reference>
  <reference>
    <citation>Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient non-compliance with paper diaries. BMJ. 2002 May 18;324(7347):1193-4.</citation>
    <PMID>12016186</PMID>
  </reference>
  <reference>
    <citation>Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient compliance with paper and electronic diaries. Control Clin Trials. 2003 Apr;24(2):182-99.</citation>
    <PMID>12689739</PMID>
  </reference>
  <reference>
    <citation>Strupp M, Schüler O, Krafczyk S, Jahn K, Schautzer F, Büttner U, Brandt T. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology. 2003 Jul 22;61(2):165-70.</citation>
    <PMID>12874393</PMID>
  </reference>
  <reference>
    <citation>Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology. 2004 May 11;62(9):1623-5.</citation>
    <PMID>15136697</PMID>
  </reference>
  <reference>
    <citation>van den Maagdenberg AM, Pietrobon D, Pizzorusso T, Kaja S, Broos LA, Cesetti T, van de Ven RC, Tottene A, van der Kaa J, Plomp JJ, Frants RR, Ferrari MD. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron. 2004 Mar 4;41(5):701-10.</citation>
    <PMID>15003170</PMID>
  </reference>
  <reference>
    <citation>van Diemen HA, Polman CH, van Dongen TM, van Loenen AC, Nauta JJ, Taphoorn MJ, van Walbeek HK, Koetsier JC. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol. 1992 Aug;32(2):123-30.</citation>
    <PMID>1510353</PMID>
  </reference>
  <reference>
    <citation>Vollmer T, Blight AR, Henney HR 3rd. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clin Ther. 2009 Oct;31(10):2215-23. doi: 10.1016/j.clinthera.2009.10.007.</citation>
    <PMID>19922892</PMID>
  </reference>
  <reference>
    <citation>Vollmer T, Henney HR 3rd. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial. Clin Ther. 2009 Oct;31(10):2206-14. doi: 10.1016/j.clinthera.2009.10.008.</citation>
    <PMID>19922891</PMID>
  </reference>
  <reference>
    <citation>Walter JT, Alviña K, Womack MD, Chevez C, Khodakhah K. Decreases in the precision of Purkinje cell pacemaking cause cerebellar dysfunction and ataxia. Nat Neurosci. 2006 Mar;9(3):389-97. Epub 2006 Feb 12.</citation>
    <PMID>16474392</PMID>
  </reference>
  <reference>
    <citation>Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83.</citation>
    <PMID>1593914</PMID>
  </reference>
  <reference>
    <citation>Weisz CJ, Raike RS, Soria-Jasso LE, Hess EJ. Potassium channel blockers inhibit the triggers of attacks in the calcium channel mouse mutant tottering. J Neurosci. 2005 Apr 20;25(16):4141-5.</citation>
    <PMID>15843617</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2011</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <last_update_submitted>February 7, 2014</last_update_submitted>
  <last_update_submitted_qc>February 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Joanna C. Jen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>episodic ataxia</keyword>
  <keyword>CACNA1A mutations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Nystagmus, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

